British Journal of Clinical Pharmacology, EarlyView.Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
Organizational-economic aspects of innovative technologies in the field of pharmacy
RUDN Journal of Medicine, 2011 This article presents the basic directions of scientific researches of the department of management and economics in pharmacy in the field of use of innovative technologies, such as research of expenses for medicinal therapy of various diseases ...
E E Loskutova +4 more
doaj
Patents and pharmaceutical drugs : understanding the pressures on developing countries [PDF]
This paper offers a discussion to the question of why there are pressures on developing countries for introducing and/or reinforcing patent protection to pharmaceutical drugs. Patent protection is an important component of a complex strategy developed by
Nogues, Julio
core
Prices of medicines: a case-study on the impact of the rate-of-return regulation in the United Kingdom [PDF]
, 1997 [eng] This work carries out an empirical evaluation of the impact of the main mechanism for regulating the prices of medicines in the UK on a variety of pharmaceutical price indices.
Borrell, Joan-Ramon
core +1 more source
Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis
British Journal of Clinical Pharmacology, EarlyView.Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley +1 more source
Two optimistic traditions in the dismal science: rationalism and the "invisible hand" [PDF]
This paper explores two traditions of optimism in economics. In one of these traditions optimism is based on the comprehension of a spontaneous (and often progressive) order in a decentralised (or market) economy – what I will call the optimism of the ...
Stan du Plessis
core
Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods [PDF]
, 2002 Cost-effectiveness analysis is now an integral part of health technology assessment and addresses the question of whether a new treatment or other health care program offers good value for money.
A H Briggs +7 more
core +1 more source
Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria
British Journal of Clinical Pharmacology, EarlyView.Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova +5 more
wiley +1 more source
Patient Preference and Adherence, 2021 Jędrzej Lewicki,1 Urszula Religioni,2 Piotr Merks3 1Department of Pharmaceutical Technology, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland; 2Collegium of Business Administration, Warsaw School of Economics, Warsaw, Poland ...
Lewicki J, Religioni U, Merks P
doaj
Is Taking a Pill a Day Good for Health Expenditures? Evidence from a Cross Section Time Series Analysis of 19 OECD Countries from 1970 – 2000 [PDF]
This paper differs in two ways from previous comparative health system research. First, it focuses on the impact of pharmaceutical expenditures on total health expenditures as trends in pharmaceutical expenditures have been blamed of being a major driver
Verbelen, Bart
core